Skip to content

Study · Not a test of the peptide alone · 2017

6 results

Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.

Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, Lindgren MC, Lipshultz LI

American journal of men's health22 Aug 2017Cited by 1 (Europe PMC)

PMID28830317 (opens in a new tab)PMCIDPMC5675260 (opens in a new tab)DOI10.1177/1557988317718662 (opens in a new tab)PepBankPUB-28830317
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Sermorelin aloneObservational studyEfficacy outcome

    In 14 men on testosterone therapy, combined GHRP-6, GHRP-2 and sermorelin raised mean serum IGF-1 from 159.5 to 239.0 ng/mL.

    In plain wordsIn 14 men on testosterone, a combination of three growth hormone-releasing peptides raised IGF-1 levels.

    Peptide
    Sermorelin
    Outcome
    IncreaseSerum IGF-1 change from baseline
    Study

    n = 14

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    IGF-1 baseline
    159.5 ng/mL
    baseline
    IGF-1 posttreatment
    239 ng/mL
    after GHRP/SERM treatment

    Source sentences

    Summary
    Mean posttreatment IGF-1 level was 239.0 (54.6) ng/mL ( p < .0001).
    3 context sentences
    Summary · context
    Mean (SD) age of the cohort was 33.2 (2.9) years, and baseline IGF-1 level was 159.5 (26.7) ng/mL.
    Summary · context
    A retrospective review of medical records was performed for 105 men on testosterone (T) therapy seeking increases in lean body mass and fat loss who were prescribed 100 mcg of GHRP-6, GHRP-2, and SERM three times daily.
    Summary · context
    Compliance with therapy was assessed, and 14 men met strict inclusion criteria.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome

    In hypogonadal men on testosterone, a regimen of GHRP‑6, GHRP-2 and sermorelin raised mean serum IGF-1 from 159.5 to 239.0 ng/mL.

    In plain wordsIn men on testosterone, a mix of GHRP‑6, GHRP-2 and sermorelin raised IGF-1 levels. The result is not specific to GHRP‑6.

    Peptide
    GHRP-6
    Outcome
    IncreaseSerum IGF-1 level after GHRP/SERM therapy
    Study

    n = 14

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Mean baseline IGF-1
    159.5 ng/mL
    baseline
    Mean posttreatment IGF-1
    239 ng/mL
    after GHRP/SERM therapy

    Source sentences

    Summary
    Mean posttreatment IGF-1 level was 239.0 (54.6) ng/mL ( p < .0001).
    4 context sentences
    Summary · context
    Mean (SD) age of the cohort was 33.2 (2.9) years, and baseline IGF-1 level was 159.5 (26.7) ng/mL.
    Summary · context
    GHRP/SERM therapy increases serum IGF-1 levels with strict compliance to thrice-daily dosing.
    Summary · context
    A retrospective review of medical records was performed for 105 men on testosterone (T) therapy seeking increases in lean body mass and fat loss who were prescribed 100 mcg of GHRP-6, GHRP-2, and SERM three times daily.
    Summary · context
    Compliance with therapy was assessed, and 14 men met strict inclusion criteria.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 03HumanNot a test of GHRP-2 aloneObservational studyEfficacy outcome

    In 14 men on testosterone therapy, a regimen of GHRP-6, GHRP‑2 and sermorelin raised mean serum IGF-1 from 159.5 to 239.0 ng/mL (p < .0001).

    In plain wordsIn men on testosterone therapy, taking GHRP-6, GHRP‑2 and sermorelin together was linked to higher IGF-1 levels than before treatment.

    Peptide
    GHRP-2
    Outcome
    IncreaseSerum IGF-1 after GHRP/SERM therapy
    Study

    n = 14

    Comparator
    Pre-treatment baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    IGF-1 baseline
    159.5 ng/mL
    before treatment
    IGF-1 post-treatment
    239 ng/mL
    after GHRP/SERM therapy

    Source sentences

    Summary
    Mean posttreatment IGF-1 level was 239.0 (54.6) ng/mL ( p < .0001).
    3 context sentences
    Summary · context
    baseline IGF-1 level was 159.5 (26.7) ng/mL.
    Summary · context
    A retrospective review of medical records was performed for 105 men on testosterone (T) therapy seeking increases in lean body mass and fat loss who were prescribed 100 mcg of GHRP-6, GHRP-2, and SERM three times daily.
    Summary · context
    Compliance with therapy was assessed, and 14 men met strict inclusion criteria.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 04HumanNot a test of Sermorelin aloneObservational studyEfficacy outcome

    In men who also took an aromatase inhibitor or tamoxifen, the IGF-1 increase with the GHRP/sermorelin combination was smaller.

    In plain wordsIn men who also took estrogen-blocking drugs, the IGF-1 rise after the peptide combination was smaller.

    Peptide
    Sermorelin
    Outcome
    MixedIGF-1 increase with aromatase inhibitor or estrogen receptor blockade
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Three of the 14 men were on an aromatase inhibitor and/or tamoxifen prior to treatment and another 4 men were coadministered an aromatase inhibitor and/or tamoxifen during treatment.
    3 context sentences
    Summary · context
    Inhibition of E production or estrogen receptor blockade resulted in smaller increases in IGF-1 levels.
    Summary · context
    A retrospective review of medical records was performed for 105 men on testosterone (T) therapy seeking increases in lean body mass and fat loss who were prescribed 100 mcg of GHRP-6, GHRP-2, and SERM three times daily.
    Summary · context
    Compliance with therapy was assessed, and 14 men met strict inclusion criteria.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  5. 05HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome

    In men on the GHRP‑6, GHRP-2 and sermorelin regimen, inhibition of estradiol production or estrogen receptor blockade was linked to smaller IGF-1 increases.

    In plain wordsIn men on a mix of GHRP‑6, GHRP-2 and sermorelin, drugs that block estrogen went with smaller IGF-1 rises.

    Peptide
    GHRP-6
    Outcome
    DecreaseIGF-1 increase with estrogen inhibition or blockade
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Inhibition of E production or estrogen receptor blockade resulted in smaller increases in IGF-1 levels.
    3 context sentences
    Summary · context
    Three of the 14 men were on an aromatase inhibitor and/or tamoxifen prior to treatment and another 4 men were coadministered an aromatase inhibitor and/or tamoxifen during treatment.
    Summary · context
    A retrospective review of medical records was performed for 105 men on testosterone (T) therapy seeking increases in lean body mass and fat loss who were prescribed 100 mcg of GHRP-6, GHRP-2, and SERM three times daily.
    Summary · context
    Compliance with therapy was assessed, and 14 men met strict inclusion criteria.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  6. 06HumanNot a test of GHRP-2 aloneObservational studyEfficacy outcome

    In men on the GHRP-6, GHRP‑2 and sermorelin regimen, inhibition of estradiol production or estrogen receptor blockade resulted in smaller IGF-1 increases.

    In plain wordsIn men taking GHRP-6, GHRP‑2 and sermorelin together, those also on estrogen-blocking drugs had smaller IGF-1 rises.

    Peptide
    GHRP-2
    Outcome
    DecreaseIGF-1 rise with aromatase inhibitor or tamoxifen
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Inhibition of E production or estrogen receptor blockade resulted in smaller increases in IGF-1 levels.
    3 context sentences
    Summary · context
    Three of the 14 men were on an aromatase inhibitor and/or tamoxifen prior to treatment and another 4 men were coadministered an aromatase inhibitor and/or tamoxifen during treatment.
    Summary · context
    A retrospective review of medical records was performed for 105 men on testosterone (T) therapy seeking increases in lean body mass and fat loss who were prescribed 100 mcg of GHRP-6, GHRP-2, and SERM three times daily.
    Summary · context
    Compliance with therapy was assessed, and 14 men met strict inclusion criteria.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 5 to 19Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 4

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 3

    10 Oct 2026, 10:21 UTC

    Study results updated

  4. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.